Global Antibody Conjugates Drugs In-Depth Industrial and Market studies 2017-2020

Albany, New York, Feb 08, 2017

"Global Antibody Conjugates Drugs Market 2016-2020" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.

Description-

ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue.

Antibodies are the proteins produced by B-cells (from bone marrow) in the immune system. These proteins attach to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies that attach to different sites of an antigen. mAbs, complex proteins with high molecular weight, are monospecific as they are the clones of a single parent cell. They are of three types, chimeric, humanized, and fully human, and are often used for therapeutic and diagnostic purposes.

Get Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=700592

** Technavios analysts forecast the global ADCs market to grow at a CAGR of 41.58% during the period 2016-2020.

– Covered in this report
The report covers the present scenario and the growth prospects of the global ADCs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of ADCs used to treat cancer.

– The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Antibody Drug Conjugates Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

– Key vendors
F. Hoffmann-La Roche AG
Seattle Genetics Inc.
Takeda Pharmaceutical Company

– Other prominent vendors
AbbVie
AbGenomics
ADC Therapeutics
Agensys
ALMAC Group
Ambrx
Astellas Pharma
AstraZeneca
Bayer HealthCare
CARBOGEN AMCIS
Celldex Therapeutics
Daiichi Sankyo
Endo Pharmaceuticals
Esperance Pharmaceuticals
Formation Biologics
Genmab
GlaxoSmithKline
Immunogen
Kairos Therapeutics
MedImmune
Mersana Therapeutics
Novartis
Oxford Biotherapeutics
Pfizer
Stemcentrx
Synthon Biopharmaceuticals
Zymeworks

– Market driver
Robust late-stage pipeline
For a full, detailed list, view our report

– Market challenge
High developmental costs
For a full, detailed list, view our report

– Market trend
Strategic alliances
For a full, detailed list, view our report

– Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?